Добірка наукової літератури з теми "Molécules recombinantes"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Molécules recombinantes".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Molécules recombinantes"
Tonnel, A. B., A. Tsicopoulos, and H. Hammad. "Les thérapeutiques du futur en allergologie. Cytokines recombinantes, anticytokines, antagonistes des récepteurs de cytokines et inhibiteurs des molécules costimulatrices." Revue Française d'Allergologie et d'Immunologie Clinique 40, no. 3 (April 2000): 295–300. http://dx.doi.org/10.1016/s0335-7457(00)80041-6.
Повний текст джерелаBonnefoy, Nathalie, Daniel Olive, and Bernard Vanhove. "Les futures générations d’anticorps modulateurs des points de contrôle de la réponse immunitaire." médecine/sciences 35, no. 12 (December 2019): 966–74. http://dx.doi.org/10.1051/medsci/2019193.
Повний текст джерелаSantos Junior, Alceu Gonçalves, Renan Eugênio Araujo Piraine, Rodrigo Casquero Cunha, Leandro Quintana Nizoli, Renato Andreotti, and Fábio Pereira Leivas Leite. "AVALIAÇÃO DE MÉTODOS PARA OBTENÇÃO DE PROTEÍNAS RECOMBINANTES." Science And Animal Health 5, no. 2 (November 6, 2017): 166. http://dx.doi.org/10.15210/sah.v5i2.11387.
Повний текст джерелаNieto Clavijo, Carlos Alfonso, Nicolás Forero Baena, and María Helena Ramírez Hernández. "Diseño y producción de diversas proteínas fusión de la nicotinamida/nicotinato mononucleótido adenilil transferasa (NMNAT) de Plasmodium falciparum." Revista Colombiana de Química 46, no. 3 (September 1, 2017): 5–10. http://dx.doi.org/10.15446/rev.colomb.quim.v46n3.63492.
Повний текст джерелаCastellanos, Jaime E., Sheilla Ledesma-Ortiz, and Jeanette Prada-Arismendy. "Producción y evaluación anti-herpética de una molécula recombinante de interferón beta." Hechos Microbiológicos 2, no. 2 (August 25, 2012): 47–54. http://dx.doi.org/10.17533/udea.hm.12649.
Повний текст джерелаBevilaqua, Vanessa Rezende, Jaqueline Rodrigues da Silva, and Vadim Ravara Viviani. "Demonstração bioluminescente de ATP com luciferase recombinante de vagalume (Amydetes vivianii Silveira & Mermudes, 2014) em aulas práticas de bioenergética." Revista de Ensino de Bioquímica 20, no. 2 (September 2, 2022): 209–28. http://dx.doi.org/10.16923/reb.v20i2.1006.
Повний текст джерелаCremonesi, Aline Sampaio. "A importância da docagem molecular no combate às bactérias multirresistentes." BIOINFO 3, no. 1 (September 21, 2023): 20. http://dx.doi.org/10.51780/bioinfo-03-20.
Повний текст джерелаMorales, Liliana, Myriam L. Velandia, María Angélica Calderon, Jaime E. Castellanos, and Jacqueline Chaparro-Olaya. "Polyclonal antibodies against recombinant dengue virus NS3 protein." Biomédica 37, no. 1 (January 24, 2017): 131. http://dx.doi.org/10.7705/biomedica.v37i1.3249.
Повний текст джерелаOstos Ortíz, Olga Lucía, Sonia Marcela Rosas Arango, and Johanna Lizeth González Devia. "Aplicaciones biotecnológicas de los microorganismos." Nova 17, no. 31 (June 15, 2019): 129–63. http://dx.doi.org/10.22490/24629448.3629.
Повний текст джерелаBlanco, Marcos Luengo. "Revisão de métodos convencionais de controle de qualidade biológico de biofármacos de origem recombinante e biossimilares e perspectivas de métodos alternativos: https://doi.org/10.31415/bjns.v1i3.36." Brazilian Journal of Natural Sciences 1, no. 3 (October 5, 2018): 7. http://dx.doi.org/10.31415/bjns.v1i3.36.
Повний текст джерелаДисертації з теми "Molécules recombinantes"
Rabu, Catherine. "Amplification ex vivo de lymphocytes T CD8 humains spécifiques à l'aide de molécules recombinantes multimérisées." Phd thesis, Université de Nantes, 2005. http://tel.archives-ouvertes.fr/tel-00339416.
Повний текст джерелаL'interaction 4-1BB/4-1BBL (CD137/CD137L) constitue un des signaux de co-stimulation impliqués dans l'activation des lymphocytes T CD8 effecteurs. Le travail présenté ici décrit pour la première fois la production et la caractérisation d'une forme fonctionnelle de 4-1BBL recombinant soluble. De plus, nous montrons qu'il est possible d'amplifier in vitro des lymphocytes T mémoires anti-CMV et anti-EBV avec des complexes HLA-peptide associés à ce 4-1BBL ou à de l'anticorps anti-CD28. L'intérêt de la co-stimulation du 4-1BB est comparée à celle du CD28 dans les 2 contextes antigéniques étudiés.
Demouveaux, Bastien. "Modification des gels de mucus par la délivrance de molécules composées de domaines CYS." Thesis, Lille 2, 2019. http://www.theses.fr/2019LIL2S029.
Повний текст джерелаMucus is a gel conserved among vertebrates and invertebrates. Its major functions arethe protection and hydration of non-keratinized epithelia. Gel-forming mucins are multidomainproteins, which self-associate together to form linear and entangled polymers toform the mucus glycoprotein matrix. The well-characterized covalent interactions, but alsonon-covalent (reversible) links, are responsible for the viscoelastic character of mucus. Themucin CYS domain is found in mucus on the surface of all secretory human mucosae. Itis very well conserved in vertebrates and very hydrophobic. Thus, it is one of the bestcandidates for establishing reversible hydrophobic bonds.The aim of this work is to study the impact of CYS domain enrichment on propertiesof mucus gels. For this, a transgenic mouse model (Tg222) and a mucus-secretingcell line (HT29-MTX E12), constitutively secreting a recombinant molecule made of 12consecutive CYS domains (rCYSx12), were developed. The effect of endogenous deliveryof rCYSx12 on mucus gel permeability, cellular motility and rheological properties wasstudied (micro- and macro-scale). Cellular models secreting a molecule made up of CYSdomains (poly-CYS) have also been developed in order to consider the exogenous deliveryof this molecule, and to study its effect in a pathological context.Endogenous delivery of rCYSx12 into the mucus of the HT29-MTX E12 cell linedecreased the permeability of the mucus gel. The secretion of rCYSx12 was also associatedwith a decrease in bacterial motility (velocity and linearity of displacement) in the mucusof the cellular and mouse models. The rheological properties of the colonic mucus weredetermined at multi-scale levels. The delivery of rCYSx12 leads to a remodeling of the mucus protein matrix by reducing its mesh size. The production of a poly-CYS moleculewas developed in the yeast Pichia pastoris and in the human cell line HEK293. UnlikeP. pastoris, the HEK293 cell line produced and secreted the poly-CYS molecule withoutapparent modifications.The rCYSx12 is of great therapeutic interest for strengthening mucus gels in pathologicalcontexts such as ulcerative colitis or intrauterine infections. The development ofmodels stably secreting the poly-CYS molecule will make it possible to carry out exogenousdelivery tests, and thus to evaluate the therapeutic potential of this molecule
Ho, Wang Yin Kiave-Yune. "Mécanismes d'action de la molécule tolérogène HLA-G au travers de la trogocytose et détermination des structures de HLA-G fonctionnelles in vivo." Paris 7, 2010. http://www.theses.fr/2010PA077102.
Повний текст джерелаHLA-G is a non-classical HLA class I molecule characterized by its tolerogenic properties. At the feto-maternal interface, HLA-G plays a key role in protecting the fetus against the immune System of the mother. The expression of HLA-G in allogeneic grafts is associated with better acceptance. Expressed by tumors, HLA-G endows them with a resistance to anti-tumor immunity. Understanding the cellular mechanisms and structures involved in the inhibitory fonctions of HLA-G is therefore a real therapeutic and diagnostic challenge. First, I studied the cellular mechanisms of inhibition by HLA-G mediated by trogocytosis and demonstrated that monocytes capture HLA-G 1 by trogocytosis from tumor cells. Unlike T lymphocytes and NK cells, monocytes that have captured HLA-G 1 do not behave as regulatory cells, but are able to transfer again HLA- Gl to other effectors (serial trogocytosis). I also showed that T cells are able to acquire the ILT2 receptor by trogocytosis from monocytes, which enables them to become sensitive to HLA-G 1. My second objective was to study the HLA-G structures that are functional in vivo. I demonstrated the existence of dimers of HLA-G2, G4 and G6, developed a detection method using ILT2 and ILT4 receptors, and determined the HLA-G structures recognized by these receptors. In particular, I demonstrated that thé ILT4 receptor recognizes the HLA-G6 isoform. Finally, T compared the efficiencies of HLA-G structures in vivo in a murine model of allogeneic skin graft
Jacopini, Sabrina. "Utilisation de la 13-Hydroperoxyde lyase recombinante d’olive dans des procédés biocatalytiques de production de composés à note verte." Thesis, Corte, 2015. http://www.theses.fr/2015CORT0016/document.
Повний текст джерелаThe hydroperoxide lyase (HPL) derives from a metabolic pathway named lipoxygenase pathway widely represented in plants and involved in the production of flavoring compounds (hexanal, 3Z-hexenal and 2E-hexenal). These volatile compounds are responsible for the fresh odor of cut grass known as "green note" and have a particularly interest for flavor and food industries. Their biosynthesis results from the oxygenation of linoleic and linolenic acids by lipoxygenase action to form fatty acid hydroperoxides, then of their cleavage by hydroperoxide lyase action. The processes of production currently used are highly polluting or lead to a low yield. To overcome these drawbacks, the use of recombinant enzymes in such processes constitutes an attractive alternative because they would allow producing these molecules in a more effective way, while benefiting from the "natural" label.A cDNA encoding for HPL (HPLwt) from black olive fruit was isolated, and in order to improve the enzyme solubility, the HPL deleted of its chloroplast transit peptide (HPLdel) was then produced. Both enzymes were expressed into E. coli (M15), purified by affinity chromatography, and characterized. They act exclusively on 13-hydroperoxide (13-HPL) and display an optimum pH at 7.5 and an optimum temperature at 25 °C. The bioconversion of 13-hydroperoxides of linoleic and linolenic acids in hexanal and 3Z-hexenal respectively, using HPLwt or HPLdel was studied. Conversion yields reach a maximum of 93 % and 68 % for hexanal production, and 73 % and 45 % for 3Z-hexenal when reactions were performed by HPLwt and HPLdel respectively.The enzyme stability was then studied. Conservations tests using 10 % glycerol (v/v) allows the maintenance of the entire activity of HPLwt and HPLdel during five weeks of storage at -80°C. Furthermore, the addition of chemical compounds such as KCl, NaCl, Na2SO4, glycine, and glycerol can increase the efficiency of both enzymes and improve the synthesis of hexanal and 3Z-hexenal by decreasing the amount of enzyme required to produce them
Gaudard, Aurélie. "Molécules favorisant le transport de l'oxygène : effets de la prise, chez l'athlète, d'érythropoi͏̈étine recombinante humaine, analogies et différences hémorhéologiques avec le sportif non dopé." Montpellier 1, 2002. http://www.theses.fr/2002MON13507.
Повний текст джерелаDescamps, Delphyne. "Rôle des molécules d'apoptose de la famille du TNF dans l'hépatite auto-immune induite par la concanavaline A et l'hépatite associée au transfert de gènes par les adénovirus recombinants." Paris 7, 2007. http://www.theses.fr/2007PA077133.
Повний текст джерелаIn order to analyze the role of death receptors in different models of hepatitis, we first constructed and characterized different recombinant adenoviruses (Ad) encoding soluble or membrane-anchored antagonists of death receptors belonging to TNFR family. These antagonists were shown to be efficient tools to inhibit apoptosis in vivo since their expression by hepatocytes prevented liver damage and mice death in different acute hepatitis models. In particular, we showed that membrane-anchored antagonists (death domain-deficients (ADD)), unable to transduce death signals, were as efficient as soluble antagonists to inhibit death ligands. Such ADD-decoy receptors act as dominant-negative receptors exerting local inhibition, while avoiding systemic neutralization of apoptosis ligands. In the second part of our work, these antagonists were used to analyze the contribution of different death ligands and death receptors in two hepatitis models. In concanavalin A (ConA)-induced hepatitis model, we showed that TNF-α is essentiel to the development of hepatitis and that FasL/Fas pathway is the major mechanism of hepatocytes destruction. On the contrary, we observed that TRAIL/DR5 pathway is involved in negative regulation of cytokines production. In the hepatitis triggered by recombinant Ad gene transfer in the liver, we showed on one hand that TNF-α centrals the recruitment of immune cells and, on the second hand, that TNF-α and IL-6 play together an important role in controlling antibody responses against Ad and transgenes
Chanut-Delalande, Hélène. "Rôle du collagène V dans l'élaboration d'une matrice extracellulaire : approche in vitro par production de la molécule recombinante et in vivo par transgénèse chez la souris." Lyon 1, 2001. http://www.theses.fr/2001LYO10194.
Повний текст джерелаGarraud, Marie. "Étude de la toxicité vasculaire de l’activateur tissulaire du plasminogène recombinant (rt-PA) après une ischémie cérébrale." Thesis, Paris 5, 2014. http://www.theses.fr/2014PA05P618/document.
Повний текст джерелаThrombolysis with recombinant tissue plasminogen activator (rt-PA) is currently the only approved pharmacological strategy for acute ischemic stroke. However, the efficacy of rt-PA is rarely complete, and arterial reocclusion can be observed. Furthermore, administration of rt-PA increases the risk of hemorrhagic transformations. Therefore, it is essential to seek mechanisms underlying the vascular toxicity of rt-PA in order to develop strategies protecting the vascular bed. Among these strategies, our laboratory has previously shown that inhibition of poly (ADP-ribose) polymerase (PARP), a nuclear enzyme, protects the blood-brain barrier, reduces hemorrhagic transformations and improves cerebral reperfusion following the post-ischemic administration of rt-PA. In this context, the aim of the present work was to establish the post-ischemic mechanisms of rt-PA-induced vascular alterations. The research was divided into (1) in vivo experiments and (2) in vitro studies to examine the effect of rt-PA on the endothelium. The in vivo studies were performed in a mouse model of thrombo-embolic stroke induced by thrombin injection in the middle cerebral artery. Our results showed that neither ischemia, nor rt-PA, nor the association to rt-PA of the potent inhibitor of PARP PJ34 alter cerebral fibrin deposits, a marker of hypoperfusion and reocclusion, at 24 hours after ischemia. We then evaluated the expression of two endothelial markers of inflammation : VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1). Our results showed that their expressions increase 24 hours after ischemia and are not modified by rt-PA. Finally, the association of PJ34 to rt-PA significantly reduced the post-ischemic expression of VCAM-1, suggesting a role for PARP in the expression of this adhesion molecule. The second part of my work was carried out in vitro in cultures of mouse brain-derived endothelial cells bEnd.3. In the presence of rt-PA, the organization and the morphology of the endothelial cells radically changed. However, these changes were associated neither to a degradation of endothelial junction proteins (occludin, VE-cadherin (vascular endothelial-cadherin)), nor to an increase in the expression of pro-inflammatory endothelial markers (VCAM-1, ICAM-1). We were also interested in a recently identified marker of endothelial dysfunction : endothelial microparticles (EMP). Our results showed that rt-PA induces a significant increase in the EMP released by bEnd.3 cells. The use of a p38 inhibitor, SB203580, and the PARP inhibitor, PJ34, reduced this increase, suggesting that p38 and PARP could be involved in the EMP production induced by rt-PA. In conclusion, this work helps to clarify the vascular effects of rt-PA. Among these effects, the highlight of EMP production, through PARP pathway, is particularly original
Gricourt, Linda. "Implication des molécules du système insuline/IGF dans la croissance et la reproduction de l'huître creuse Crassostrea gigas : effets biologiques in vitro d'un ligand hétérologue (IGF-1 recombinant humain), caractérisation et expression d'un récepteur homologue de type insuline." Caen, 2002. http://www.theses.fr/2002CAEN2013.
Повний текст джерелаКниги з теми "Molécules recombinantes"
Ryadnov, Maxim. Bionanodesign: Old Forms for New Functions. Royal Society of Chemistry, The, 2021.
Знайти повний текст джерелаRyadnov, Maxim. Bionanodesign: Old Forms for New Functions. Royal Society of Chemistry, The, 2020.
Знайти повний текст джерелаBionanodesign: Following nature's touch. Cambridge: RSC Publishing, 2009.
Знайти повний текст джерелаBionanodesign: Following Nature's Touch. Royal Society of Chemistry, The, 2009.
Знайти повний текст джерелаЧастини книг з теми "Molécules recombinantes"
Furlan, Renata Ligia de Araújo. "PLATAFORMAS MICROBIANAS PARA PRODUÇÃO DE BIOFÁRMACOS." In Biotecnologia Microbiana - Volume 1, 11–24. Editora Científica Digital, 2023. http://dx.doi.org/10.37885/230111831.
Повний текст джерелаТези доповідей конференцій з теми "Molécules recombinantes"
Kraschowetz, Stefanie, DOUGLAS BORGES DE FIGUEIREDO, Rafaela Tais Zanardo, Fara A. P. Eguia, Thiago Rojas Converso, and Viviane Maimoni Gonçalves. "Clonagem e expressão de uma molécula recombinante híbrida de duas proteínas de Streptococcus pneumoniae." In Simpósio Nacional de Bioprocessos e Simpósio de Hidrólise Enzimática de Biomassa. Campinas - SP, Brazil: Galoá, 2015. http://dx.doi.org/10.17648/sinaferm-2015-33390.
Повний текст джерелаKRASCHOWETZ, S., D. B. FIGUEIREDO, G. CAMPANI JR, G. G. SILVA, T. C. ZANGIROLAMI, L. C. C. LEITE, J. CABRERA-CRESPO, and V. M. GONçALVES. "PRODUÇÃO DE UMA MOLÉCULA RECOMBINANTE HÍBRIDA DE DUAS PROTEÍNAS DE Streptococcus pneumoniae: PspA94-PdT." In XX Congresso Brasileiro de Engenharia Química. São Paulo: Editora Edgard Blücher, 2015. http://dx.doi.org/10.5151/chemeng-cobeq2014-1318-19907-147206.
Повний текст джерелаCarneiro, Luis Felipe Ferreira, Osmar Júnior Da Silva Silva, Matteus Gomes De Oliveira, and Salomão Bruno Dos Santos Brasil. "TERAPIA GÊNICA NO TRATAMENTO DE ANEMIA FALCIFORME, UMA REVISÃO DE LITERATURA." In II Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/hematoclil/133.
Повний текст джерелаBridi, Vanessa, Gabriela Alves Carvalho Duarte, Dhullya Eduarda Resende Santos, and Hanstter Hallison Alves Rezende. "BIOFÁRMACOS: DESAFIOS ENFRENTADOS NA PRODUÇÃO NACIONAL." In I Congresso de Engenharia de Biotecnologia. Revista Multidisciplinar de Educação e Meio Ambiente, 2021. http://dx.doi.org/10.51189/rema/1376.
Повний текст джерела